The 2022 list of medical technologies approved for innovation funding (NUB) released in Germany

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021.

Out of 868 submitted technologies, 251 (29%) received the positive status 1, which means that the suggested procedure or medical device met the NUB criteria, so now the hospitals can negotiate the innovation funding for these technologies with the sickness funds.

Furthermore, 32 (4%) technologies received differentiated status, which means that status 1 can be granted only under certain conditions.

The complete list of medical technologies (n=84, excluding pharmaceuticals), which obtained status 1, is provided below. The technologies are listed according to the number of received applications for funding. The technologies with differentiated status were not included in the list.

1. Insertion of coated (covered) stents with the bioactive surface for peripheral vessels
2. Covered endoprostheses with the bioactive surface for dialysis shunt revision
3. Ascites treatment with a fully implantable pump
4. External stabilization scaffold for anastomosis of an AV shunt as part of shunt surgery
5. Endovascular placement of an internal AV shunt using magnetically guided high-frequency energy
6. Intra-aortic catheter with paracorporeal membrane pump for circulatory support
7. Flow-reducing wire mesh in the coronary sinus
8. Hemodynamically effective implant for the endovascular treatment of intracranial aneurysms and cervical vessels supplying the brain
9. Intraaneurysmal hemodynamically effective implant for the endovascular treatment of intracranial aneurysms
10. Removable, ultra-soft microcoils for intracranial therapy of vascular malformations and aneurysms
11. Transcatheter implantation of an interatrial shunt device for the treatment of heart failure
12. Percutaneous transluminal insertion of an atrial septal implant for the treatment of heart failure
13. Implantation of a gastric pacemaker
14. Extracorporeal neurostimulation system for the peripheral nervous system
15. Endovascular implantation of an extracorporeal centrifugal pump for circulatory support
16. Focal photodynamic therapy with padeliporfin for the treatment of localized prostate cancer
17. Administration of CAR-T cells for the treatment of hematological diseases
18. Therapy of scoliosis using magnetically controlled rods
19. Vertebral bodies growth modulation technique
20. Transfer of virus-specific donor immune cells after allogeneic stem cell transplantation
21. Endovascular mitral valve annuloplasty with annuloplasty band
22. Transapical mitral valve reconstruction via implantation of neochordae (polytetrafluoroethylene, PTFE)
23. Temporomandibular joint endoprosthesis (total replacement)
24. Mesenchymal stem cells
25. Minimally invasive left ventricle reconstruction with a myocardial anchoring system
26. Percutaneous caval valve stent placement
27. Intra-aortic balloon occlusion with extracorporeal circulation
28. The wireless cardiac pacing system of the left ventricle for cardiac resynchronization therapy
29. Insertion of coated (covered) stents with the bioactive surface for peripheral and other vessels
30. Catheter-based implant for the treatment of left ventricular cardiac motility disorders
31. Percutaneous transluminal implantation of an interatrial shunt for the treatment of heart failure with preserved or reduced left ventricular ejection fraction
32. Therapy of scoliosis using a screw-rod system that grows with the patient
33. Endovascular placement of a peripheral AV fistula by direct current
34. Insertion of coated (covered) stents with a bioactive surface for intra-abdominal, cranial, or peripheral vessels
35. Implantation of a heart valve that grows with the patient
36. Endo-Exo prosthesis
37. Endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency
38. Replacement of the pulmonary trunk or parts of the aorta with an acellular allograft
39. Thrombectomy of pulmonary vessels using the disc retriever system
40. Performing a sleeve resection, endoscopically
41. Radioligand therapy with Actinium-225-PSMA ligands
42. Insertion of a colorectal bypass system to protect the anastomosis
43. Radioimmunotherapy with anti-CD19, anti-CD45, and anti-CD66 antibodies
44. Endoscopic intratumoral injection of phosphorus-32-labeled microparticles under ultrasound guidance in irresectable locally advanced pancreatic tumors
45. Mesenchymal stem cells in therapy-resistant venous ulcers
46. Apicoaortal, valve-bearing conduit
47. Implant for direct acoustic stimulation of the cochlea (DACI)
48. Insertion of coated (covered) stents with the bioactive surface for visceral and supra-aortic vessels
49. Endoscopic thermal ablation of the duodenal mucosa to reduce insulin resistance
50. Fetoscopic drainage therapy
51. Continuous amniotic infusion using a subcutaneously implanted port system
52. Acoustic neurinoma surgery with simultaneous cochlea implantation
53. Endovascular mitral valve annuloplasty with anchorage of the suture
54. Implantation of an intraocular lens with a magnification factor in macular degeneration
55. Thyroplasty implant with the possibility of postoperative adjustment of vocal fold position
56. Epiretinal retinal prosthesis
57. Fetoscopic tracheal balloon closure in diaphragmatic hernia and premature rupture of the membranes
58. Lutetium-177- or Yttrium-90 Pentixafor therapy
59. Intracavitary radiotherapy with iodine-125
60. Telemetrically adjustable pulmonary artery banding
61. Closure of umbilical cord and intrafetal vessels using percutaneous ultrasound-guided radiofrequency ablation or fetoscopic laser ablation
62. Boston keratoprosthesis
63. Fetoscopic opening of narrowed semilunar valves and the foramen ovale
64. Auditory brainstem implant
65. Fetoscopic therapy of fetal supraventricular tachycardia and occlusion of the larynx or trachea
66. Keratoprosthesis, biologically coated
67. Uterine shield closure after fetoscopic surgery
68. Growth endoprostheses
69. Allogeneic hepatocyte transplantation
70. Percutaneous transthoracic tricuspid valve replacement
71. Radionuclide therapy with lutetium-177-bisphosphonate in bone metastases of prostate cancer
72. Auditory middle brain implant
73. Artificial larynx after total laryngectomy
74. Radionuclide therapy with iodine-131-azetidinylamide in metastatic adrenal carcinoma
75. Subretinal active implant
76. Uterus transplantation
77. Treatment of lethal epidermolysis bullosa junctionalis (M. Herlitz type) by transplanting haploidentical bone marrow and skin from the same donor
78. Treatment of children with rhabdomyosarcomas of the bladder/prostate/rectum/perineal region with organ-preserving surgery and interstitial HDR brachytherapy
79. Joint transplantations with thin-layered, fresh, living, allogeneic cartilage or bone material
80. Gene therapy with autologous CD34+ enriched cells with ARSAGs for the treatment of metachromatic leukodystrophy
81. Implantation of an intraocular lens in patients with macular diseases
82. Combined renal and stem cell transplantation (living donation)
83. Radionuclide therapy with iodine-131 metomidate
84. Complete face transplantation

Seven new technologies (thrombectomy of pulmonary vessels using the disc retriever system, insertion of a colorectal bypass system to protect the anastomosis, endoscopic-intratumoral injection of phosphorus-32-labeled microparticles under ultrasound guidance in irresectable locally advanced pancreatic tumors, mesenchymal stem cells in therapy-resistant venous ulcers, endoscopic thermal ablation of the duodenal mucosa to reduce insulin resistance, implantation of an intraocular lens with a magnification factor in macular degeneration, implantation of an intraocular lens in patients with macular diseases) received status 1 in comparison with the 2021 list.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.